Updates on current evidence for biologics in chronic rhinosinusitis

Keyphrases

• Anti-IL-4 50%
• Benralizumab 50%
• Dupilumab 100%
• IL-4 Receptor 50%
• Large-scale Clinical Trial 50%
• Mepolizumab 50%
• Persistent Symptoms 50%
• Reslizumab 50%

Medicine and Dentistry

• Benralizumab 50%
• Dupilumab 100%
• Functional Endoscopic Sinus Surgery 50%
• Interleukin 4 50%
• Mepolizumab 50%
• Reslizumab 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Benralizumab 50%
• Dupilumab 100%
• Interleukin 4 50%
• Mepolizumab 50%
• Reslizumab 50%